Glucagon-like peptide-1 receptor
Glucagon-like peptide-1 receptor (GLP-1R) is a G protein-coupled receptor that binds glucagon-like peptide-1 (GLP-1), a hormone involved in the regulation of blood glucose levels. The receptor is expressed in various tissues, including the pancreas, brain, and heart, and plays a crucial role in glucose homeostasis and cardiovascular function.
Structure[edit | edit source]
The GLP-1R is a member of the class B1 family of G protein-coupled receptors. It is a transmembrane protein composed of seven alpha-helical segments connected by three extracellular and three intracellular loops. The N-terminal domain of the receptor is responsible for ligand binding, while the C-terminal domain is involved in receptor activation and signal transduction.
Function[edit | edit source]
Upon binding of GLP-1, the GLP-1R activates the adenylate cyclase enzyme, leading to an increase in the intracellular concentration of cyclic AMP (cAMP). This, in turn, activates protein kinase A (PKA) and exchange protein directly activated by cAMP (EPAC), which mediate the downstream effects of GLP-1R activation.
In the pancreas, GLP-1R activation stimulates insulin secretion from beta cells in a glucose-dependent manner. In the brain, it promotes satiety and reduces food intake. In the heart, it improves cardiac function and protects against ischemic injury.
Clinical significance[edit | edit source]
GLP-1R is a target for the treatment of type 2 diabetes. GLP-1R agonists, such as exenatide and liraglutide, are used to increase insulin secretion, suppress glucagon release, and reduce appetite. These drugs have been shown to improve glycemic control and promote weight loss in patients with type 2 diabetes.
In addition, research is ongoing to explore the potential benefits of GLP-1R activation in the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and cardiovascular diseases.
See also[edit | edit source]
This GPCR-related article is a stub. You can help WikiMD by expanding it.
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
